1. Landsberg G. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2005;29(3):471-9. doi:http://dx.doi.org/10.1016/j.pnpbp.2004.12.012.
2. Fast R, Schutt T, Toft N, Moller A, Berendt M. An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival, and risk factors. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2013;27(4):822-9. doi:10.1111/jvim.12109.
3. Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ. Under diagnosis of canine cognitive dysfunction: a cross-sectional survey of older companion dogs. Veterinary journal (London, England : 1997). 2010;184(3):277-81. doi:10.1016/j.tvjl.2009.11.007.
4. Vite CH, Head E. Aging in the canine and feline brain. The Veterinary clinics of North America Small animal practice. 2014;44(6):1113-29. doi:10.1016/j.cvsm.2014.07.008.
5. Schmidt F, Boltze J, Jäger C, Hofmann S, Willems N, Seeger J et al. Detection and Quantification of β-Amyloid, Pyroglutamyl Aβ, and Tau in Aged Canines. Journal of Neuropathology & Experimental Neurology. 2015;74(9):912-23. doi:10.1097/nen.0000000000000230.
6. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ. Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging. 1993;14(6):547-60.
7. Schutt T, Toft N, Berendt M. Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2015;29(6):1569-77. doi:10.1111/jvim.13633.
8. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW. The canine as an animal model of human aging and dementia. Neurobiology of Aging. 1996;17(2):259-68. doi:http://dx.doi.org/10.1016/0197-4580(95)02060-8.
9. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. β-Amyloid Accumulation Correlates with Cognitive Dysfunction in the Aged Canine. Neurobiology of Learning and Memory. 1996;66(1):11-23. doi:http://dx.doi.org/10.1006/nlme.1996.0039.
10. Head E, Rofina J, Zicker S. Oxidative stress, aging, and central nervous system disease in the canine model of human brain aging. The Veterinary clinics of North America Small animal practice. 2008;38(1):167-78, vi. doi:10.1016/j.cvsm.2007.10.002.
11. Yu CH, Song GS, Yhee JY, Kim JH, Im KS, Nho WG et al. Histopathological and Immunohistochemical Comparison of the Brain of Human Patients with Alzheimer’s Disease and the Brain of Aged Dogs with Cognitive Dysfunction. Journal of Comparative Pathology. 2011;145(1):45-58. doi:http://dx.doi.org/10.1016/j.jcpa.2010.11.004.
12. Czasch S, Paul S, Baumgärtner W. A comparison of immunohistochemical and silver staining methods for the detection of diffuse plaques in the aged canine brain. Neurobiology of Aging. 2006;27(2):293-305. doi:http://dx.doi.org/10.1016/j.neurobiolaging.2005.02.017.
13. Rubio-Perez JM, Morillas-Ruiz JM. A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines. The Scientific World Journal. 2012;2012:756357. doi:10.1100/2012/756357.
14. Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015;52:1-18. doi:10.1016/j.npep.2015.06.008.
15. Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernández J, Campos-Peña V. Inflammatory process in Alzheimer's Disease. Frontiers in Integrative Neuroscience. 2013;7:59. doi:10.3389/fnint.2013.00059.
16. Khemka VK, Ganguly A, Bagchi D, Ghosh A, Bir A, Biswas A et al. Raised Serum Proinflammatory Cytokines in Alzheimer’s Disease with Depression. Aging and Disease. 2014;5(3):170-6. doi:10.14336/AD.2014.0500170.
17. Sun Q, Xie N, Tang B, Li R, Shen Y. Alzheimer’s Disease: From Genetic Variants to the Distinct Pathological Mechanisms. Frontiers in Molecular Neuroscience. 2017;10(319). doi:10.3389/fnmol.2017.00319.
18. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63(3):287-303. doi:10.1016/j.neuron.2009.06.026.
19. Prpar Mihevc S, Majdič G. Canine Cognitive Dysfunction and Alzheimer's Disease - Two Facets of the Same Disease? Frontiers in neuroscience. 2019;13:604-. doi:10.3389/fnins.2019.00604.
20. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL et al. Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests. Molecular Psychiatry. 2009;14(5):469-86. doi:10.1038/mp.2008.96.
21. Colle MA, Hauw JJ, Crespeau F, Uchihara T, Akiyama H, Checler F et al. Vascular and parenchymal Aβ deposition in the aging dog: correlation with behavior. Neurobiology of Aging. 2000;21(5):695-704. doi:http://dx.doi.org/10.1016/S0197-4580(00)00113-5.
22. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009;14(5):469-86. doi:10.1038/mp.2008.96.
23. Garai K, Posey AE, Li X, Buxbaum JN, Pappu RV. Inhibition of amyloid beta fibril formation by monomeric human transthyretin. Protein Sci. 2018;27(7):1252-61. doi:10.1002/pro.3396.
24. Nalivaeva NN, Turner AJ. Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. British Journal of Pharmacology. 2019;176(18):3447-63. doi:10.1111/bph.14593.
25. Yoon S-S, Jo SA. Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease. Biomol Ther (Seoul). 2012;20(3):245-55. doi:10.4062/biomolther.2012.20.3.245.
26. Osella MC, Re G, Odore R, Girardi C, Badino P, Barbero R et al. Canine cognitive dysfunction syndrome: Prevalence, clinical signs and treatment with a neuroprotective nutraceutical. Applied Animal Behaviour Science. 2007;105(4):297-310. doi:http://dx.doi.org/10.1016/j.applanim.2006.11.007.
27. Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ. The canine cognitive dysfunction rating scale (CCDR): A data-driven and ecologically relevant assessment tool. The Veterinary Journal. 2011;188(3):331-6. doi:http://dx.doi.org/10.1016/j.tvjl.2010.05.014.
28. Madari A, Farbakova J, Katina S, Smolek T, Novak P, Weissova T et al. Assessment of severity and progression of canine cognitive dysfunction syndrome using the CAnine DEmentia Scale (CADES). Applied Animal Behaviour Science. 2015;171:138-45. doi:http://dx.doi.org/10.1016/j.applanim.2015.08.034.
29. Landsberg GM, Nichol J, Araujo JA. Cognitive Dysfunction Syndrome: A Disease of Canine and Feline Brain Aging. Veterinary Clinics of North America: Small Animal Practice. 2012;42(4):749-68. doi:http://dx.doi.org/10.1016/j.cvsm.2012.04.003.
30. Schütt T, Toft N, Berendt M. A comparison of 2 screening questionnaires for clinical assessment of canine cognitive dysfunction. Journal of Veterinary Behavior: Clinical Applications and Research. 2015;10(6):452-8. doi:http://dx.doi.org/10.1016/j.jveb.2015.07.036.
31. Ozawa M, Inoue M, Uchida K, Chambers JK, Takeuch Y, Nakayama H. Physical signs of canine cognitive dysfunction. J Vet Med Sci. 2019;81(12):1829-34. doi:10.1292/jvms.19-0458.
32. Benjanirut C, Wongsangchan C, Setthawong P, Pradidtan W, Daechawattanakul S, Angkanaporn K. Prevalence and risk factors for canine cognitive dysfunction syndrome in Thailand. The Thai Journal of Veterinary Medicine. 2018;48(3):453-61.
33. Gonzalez-Martinez A, Rosado B, Pesini P, Suarez ML, Santamarina G, Garcia-Belenguer S et al. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. Exp Gerontol. 2011;46(7):590-6. doi:10.1016/j.exger.2011.02.013.
34. Shanthi KB, Krishnan S, Rani P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease. SAGE Open Medicine. 2015;3:2050312115598250. doi:10.1177/2050312115598250.
35. Cheng Z, Yin J, Yuan H, Jin C, Zhang F, Wang Z et al. Blood-Derived Plasma Protein Biomarkers for Alzheimer's Disease in Han Chinese. Frontiers in aging neuroscience. 2018;10:414-. doi:10.3389/fnagi.2018.00414.
36. Baker SK, Chen Z-L, Norris EH, Revenko AS, MacLeod AR, Strickland S. Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences. 2018;115(41):E9687-E96. doi:10.1073/pnas.1811172115.
37. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2003;16(3):136-44. doi:10.1159/000071001.
38. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129(11):3042-50. doi:10.1093/brain/awl279.
39. Dey KK, Wang H, Niu M, Bai B, Wang X, Li Y et al. Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer's disease. Clin Proteomics. 2019;16:16-. doi:10.1186/s12014-019-9237-1.
40. Schmidt F, Boltze J, Jager C, Hofmann S, Willems N, Seeger J et al. Detection and Quantification of beta-Amyloid, Pyroglutamyl Abeta, and Tau in Aged Canines. J Neuropathol Exp Neurol. 2015;74(9):912-23. doi:10.1097/nen.0000000000000230.
41. Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi:10.1159/000048642.
42. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(2):372-81.
43. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2011;26(2):365-75. doi:10.3233/JAD-2011-101977.
44. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics. 2005;5(13):3304-13. doi:10.1002/pmic.200402021.
45. Kanekiyo T, Liu C-C, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012;32(46):16458-65. doi:10.1523/JNEUROSCI.3987-12.2012.
46. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(15):8850-5. doi:10.1073/pnas.151261398.
47. Trouw L, Nielsen H, Minthon L, Londos E, Landberg G, Veerhuis R et al. C4b-binding protein in Alzheimer's disease: Binding to Aβ1-42 and to dead cells. Molecular immunology. 2008;45:3649-60. doi:10.1016/j.molimm.2008.04.025.
48. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2012;32(3):599-608. doi:10.3233/JAD-2012-120820.
49. Ahn HJ, Chen Z-L, Zamolodchikov D, Norris EH, Strickland S. Interactions of β-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer's disease. Curr Opin Hematol. 2017;24(5):427-31. doi:10.1097/MOH.0000000000000368.
50. Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. International journal of clinical practice. 2008;62(7):1070-5. doi:10.1111/j.1742-1241.2007.01268.x.
51. Oijen Mv, Witteman JC, Hofman A, Koudstaal PJ, Breteler MMB. Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia. Stroke. 2005;36(12):2637-41. doi:doi:10.1161/01.STR.0000189721.31432.26.
52. da Costa G, Ribeiro-Silva C, Ribeiro R, Gilberto S, Gomes RA, Ferreira A et al. Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease. PLOS ONE. 2015;10(7):e0125392. doi:10.1371/journal.pone.0125392.
53. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging. 2007;28(7):977-86. doi:10.1016/j.neurobiolaging.2006.05.016.
54. Stott DJ, Robertson M, Rumley A, Welsh P, Sattar N, Packard CJ et al. Activation of hemostasis and decline in cognitive function in older people. Arteriosclerosis, thrombosis, and vascular biology. 2010;30(3):605-11. doi:10.1161/atvbaha.109.199448.
55. Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ et al. An anemia of Alzheimer's disease. Molecular Psychiatry. 2014;19(11):1227-34. doi:10.1038/mp.2013.178.
56. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Molecular Brain Research. 2003;118(1):140-6. doi:https://doi.org/10.1016/j.molbrainres.2003.08.005.
57. Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One. 2012;7(6):e34078. doi:10.1371/journal.pone.0034078.
58. Ma C, Li J, Bao Z, Ruan Q, Yu Z. Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men. BioMed research international. 2015;2015:481621. doi:10.1155/2015/481621.
59. Hone E, Lim F, Martins I. Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease. 2019. p. 189-231.
60. Rezeli M, Zetterberg H, Blennow K, Brinkmalm A, Laurell T, Hansson O et al. Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer’s disease and other neurodegenerative diseases. EuPA Open Proteomics. 2015;8:137-43. doi:https://doi.org/10.1016/j.euprot.2015.07.012.
61. Youssef SA, Capucchio MT, Rofina JE, Chambers JK, Uchida K, Nakayama H et al. Pathology of the Aging Brain in Domestic and Laboratory Animals, and Animal Models of Human Neurodegenerative Diseases. Veterinary pathology. 2016;53(2):327-48. doi:10.1177/0300985815623997.
62. Wolfe CM, Fitz NF, Nam KN, Lefterov I, Koldamova R. The Role of APOE and TREM2 in Alzheimer's Disease-Current Understanding and Perspectives. International journal of molecular sciences. 2018;20(1):81. doi:10.3390/ijms20010081.
63. Ciccone L, Shi C, di Lorenzo D, Van Baelen AC, Tonali N. The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1. Molecules (Basel, Switzerland). 2020;25(10). doi:10.3390/molecules25102439.
64. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2007;27(5):909-18. doi:10.1038/sj.jcbfm.9600419.
65. Buxbaum JN, Johansson J. Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System. Frontiers in neuroscience. 2017;11:119-. doi:10.3389/fnins.2017.00119.
66. Yang C, Wang H, Li C, Niu H, Luo S, Guo X. Association between clusterin concentration and dementia: a systematic review and meta-analysis. Metabolic Brain Disease. 2019;34(1):129-40. doi:10.1007/s11011-018-0325-0.
67. Uchida K, Shan L, Suzuki H, Tabuse Y, Nishimura Y, Hirokawa Y et al. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimers Dement (Amst). 2015;1(2):270-80. doi:10.1016/j.dadm.2015.04.003.
68. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67(7):739-48. doi:10.1001/archgenpsychiatry.2010.78.
69. Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Frontiers in neuroscience. 2019;13:164-. doi:10.3389/fnins.2019.00164.
70. Gupta A, Watkins A, Thomas P, Majer R, Habubi N, Morris G et al. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. International journal of clinical practice. 2005;59(1):52-7. doi:10.1111/j.1742-1241.2004.00143.x.